NEWRON PHARMACEUT. EO-20 - Asset Resilience Ratio
NEWRON PHARMACEUT. EO-20 (NP5) has an Asset Resilience Ratio of 26.97% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read NEWRON PHARMACEUT. EO-20 (NP5) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2024)
This chart shows how NEWRON PHARMACEUT. EO-20's Asset Resilience Ratio has changed over time. See NEWRON PHARMACEUT. EO-20 book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down NEWRON PHARMACEUT. EO-20's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see NP5 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €16.56 Million | 26.97% |
| Total Liquid Assets | €16.56 Million | 26.97% |
Asset Resilience Insights
- Very High Liquidity: NEWRON PHARMACEUT. EO-20 maintains exceptional liquid asset reserves at 26.97% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
NEWRON PHARMACEUT. EO-20 Industry Peers by Asset Resilience Ratio
Compare NEWRON PHARMACEUT. EO-20's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for NEWRON PHARMACEUT. EO-20 (2009–2024)
The table below shows the annual Asset Resilience Ratio data for NEWRON PHARMACEUT. EO-20.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.53% | €2.89 Million ≈ $3.38 Million |
€63.91 Million ≈ $74.72 Million |
-19.68pp |
| 2023-12-31 | 24.21% | €6.26 Million ≈ $7.32 Million |
€25.87 Million ≈ $30.24 Million |
-0.93pp |
| 2022-12-31 | 25.14% | €9.35 Million ≈ $10.93 Million |
€37.20 Million ≈ $43.48 Million |
+6.17pp |
| 2021-12-31 | 18.97% | €9.57 Million ≈ $11.19 Million |
€50.49 Million ≈ $59.02 Million |
-16.26pp |
| 2020-12-31 | 35.23% | €18.04 Million ≈ $21.09 Million |
€51.20 Million ≈ $59.86 Million |
+6.85pp |
| 2019-12-31 | 28.38% | €17.11 Million ≈ $20.00 Million |
€60.29 Million ≈ $70.48 Million |
+1.33pp |
| 2018-12-31 | 27.05% | €16.23 Million ≈ $18.97 Million |
€60.00 Million ≈ $70.15 Million |
+0.43pp |
| 2017-12-31 | 26.62% | €19.44 Million ≈ $22.73 Million |
€73.02 Million ≈ $85.37 Million |
+20.40pp |
| 2016-12-31 | 6.22% | €3.52 Million ≈ $4.12 Million |
€56.59 Million ≈ $66.16 Million |
-4.87pp |
| 2015-12-31 | 11.09% | €4.92 Million ≈ $5.75 Million |
€44.38 Million ≈ $51.88 Million |
-7.65pp |
| 2014-12-31 | 18.74% | €6.95 Million ≈ $8.12 Million |
€37.07 Million ≈ $43.34 Million |
+1.48pp |
| 2013-12-31 | 17.26% | €5.46 Million ≈ $6.38 Million |
€31.62 Million ≈ $36.96 Million |
+9.10pp |
| 2012-12-31 | 8.16% | €3.64 Million ≈ $4.26 Million |
€44.65 Million ≈ $52.20 Million |
+4.30pp |
| 2009-12-31 | 3.85% | €1.60 Million ≈ $1.88 Million |
€41.68 Million ≈ $48.73 Million |
-- |
About NEWRON PHARMACEUT. EO-20
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's… Read more